Evommune (EVMN) Chief Scientific Officer awarded 69,315 stock options at $26.77

Rhea-AI Filing Summary

Patel Jeegar Pravinkumar reported acquisition or exercise transactions in this Form 4 filing.

Evommune, Inc. Chief Scientific Officer Jeegar Pravinkumar Patel received an employee stock option grant for 69,315 shares of common stock. The option has a strike price of $26.77 per share and expires on April 15, 2036, with no cash paid for the grant itself.

According to the vesting terms, one quarter of the option vests on the first anniversary of the grant date. The remaining three quarters vest in 36 equal monthly installments, contingent on Patel’s continuous service with the company. After this award, he holds 69,315 derivative securities directly.

Insider Trade Summary

1 transaction reported

Mixed 1 txn

Insider Patel Jeegar Pravinkumar

Role Chief Scientific Officer

Type	Security	Shares	Price	Value
Grant/Award	Employee Stock Option (Right to Buy)	69,315	$0.00	--

Holdings After Transaction: Employee Stock Option (Right to Buy) — 69,315 shares (Direct)

Footnotes (1)

1. [object Object]

Key Figures

Options granted: 69,315 options Exercise price: $26.77 per share Underlying shares: 69,315 shares +4 more

7 metrics

Options granted 69,315 options Employee stock option grant to Chief Scientific Officer

Exercise price $26.77 per share Strike price for employee stock options

Underlying shares 69,315 shares Evommune common stock underlying the options

Expiration date April 15, 2036 Option term end for this grant

Holdings after transaction 69,315 derivative securities Total options held by Patel following grant

Initial vesting portion 25% of options Vests on first anniversary of grant date

Remaining vesting schedule 36 monthly installments After first anniversary, subject to continuous service

Key Terms

Employee Stock Option (Right to Buy), vesting, grant date, Chief Scientific Officer

4 terms

Employee Stock Option (Right to Buy) financial

"security_title: "Employee Stock Option (Right to Buy)""

vesting financial

"shares subject to the option award shall vest on the first anniversary"

Vesting is the process by which you earn full ownership of something, like company stock or a retirement benefit, over time. It’s like earning the right to keep a gift piece by piece the longer you stay with a company, making sure employees stay committed before they receive all the benefits.

grant date financial

"on the first anniversary of the grant date and the remaining shares"

The grant date is the day a company formally gives an employee or contractor the right to receive stock-based compensation, such as stock options or restricted shares. It matters to investors because it fixes key terms—like the price, the start of the ownership clock, and when the award will affect the company’s financial statements and share count—so it can influence dilution, reported expenses, and potential future selling pressure.

Chief Scientific Officer financial

"officer_title: "Chief Scientific Officer""

Form 4 Insider Transactions: What Each Field Means →

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Patel Jeegar Pravinkumar

(Last) (First) (Middle)

C/O EVOMMUNE, INC.

1891 PAGE MILL ROAD

(Street)

PALO ALTO CALIFORNIA 94304

(City) (State) (Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
Evommune, Inc. [ EVMN ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	Chief Scientific Officer

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
04/16/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Employee Stock Option (Right to Buy)	$26.77	04/16/2026		A		69,315		(1)	04/15/2036	Common Stock	69,315	$0.00	69,315	D

Explanation of Responses:

1. One fourth (1/4) of the shares subject to the option award shall vest on the first anniversary of the grant date and the remaining shares subject to the option shall vest in thirty-six (36) equal monthly installments thereafter, subject to the Reporting Person's continuous service through such vesting date.

Remarks:

	/s/ Gregory S. Moss, Attorney-in-Fact	04/17/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)

FAQ

What insider transaction did Evommune (EVMN) report for Jeegar Patel?

Evommune reported that Chief Scientific Officer Jeegar Pravinkumar Patel received an employee stock option grant for 69,315 shares. These options give him the right to buy Evommune common stock at a fixed price in the future, subject to a multi-year vesting schedule.

How many Evommune (EVMN) options were granted and at what price?

Jeegar Patel was granted 69,315 employee stock options tied to Evommune common stock. The options have an exercise price of $26.77 per share, meaning he can purchase shares at this fixed price once they vest, regardless of future market price.

When do Jeegar Patel’s Evommune (EVMN) stock options vest?

One quarter of the 69,315 options vest on the first anniversary of the grant date. The remaining options vest in 36 equal monthly installments afterward, provided Patel continues serving Evommune throughout the entire vesting period.

What is the expiration date of the Evommune (EVMN) stock options granted to Patel?

The employee stock options granted to Jeegar Patel expire on April 15, 2036. If unexercised by that date, the options lapse. This long-dated term gives him a lengthy window to exercise after vesting, subject to company and plan rules.

Did Jeegar Patel buy or sell any Evommune (EVMN) shares in this Form 4?

No open-market buy or sell occurred; the Form 4 reports a grant of stock options as compensation. Patel acquired rights to purchase 69,315 shares at $26.77 per share, with vesting over time, and no immediate market transaction took place.